Bixel K, Vetter M, Davidson B, et al. - Researchers performed this retrospective review to compare outcomes of patients with advanced ovarian cancer who received intraperitoneal (IP) chemotherapy vs intravenous (IV) chemotherapy after neoadjuvant chemotherapy (NACT) and interval tumor reductive surgery (TRS). Cases with an ECOG PS > 1, treated with > 6 cycles of NACT or postoperative chemotherapy, and/or managed with bevacizumab during primary therapy, were eliminated from this study. Participants included 134 patients. The estimated median progression free survival (PFS) was 3 months longer in the IP arm, but no significant difference was evident in overall survival. Decreased PFS was reported in relation to the increasing number of NACT cycles and residual disease at completion of TRS, in univariate analysis, while IP chemotherapy was found to be related to increased PFS. In multivariate analysis, these links persisted. Findings revealed that an improved PFS was afforded by IP vs IV chemotherapy after NACT and optimal interval TRS, without significant differences in toxicity.